Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1

Biochemical Pharmacology

Volumn 78, Issue 4, 2009, Pages 344-354

  Cabello, Christopher M ^a   Bair III, Warner B ^a   Bause, Alexandra S ^a   Wondrak, Georg T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

2,6 Dichlorophenolindophenol; Hsp70B'; Melanoma; NQO1; Oxidative stress; Xenograft

Indexed keywords

2,6 DICHLOROPHENOLINDOPHENOL; DICOUMAROL; EARLY GROWTH RESPONSE FACTOR 1; GLUTATHIONE; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNODETECTION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; TARGET CELL; UPREGULATION;

2,6-DICHLOROINDOPHENOL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HEME OXYGENASE-1; HUMANS; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, SCID; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349127583     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.016     Document Type: Article

References (60)

1. Laurent A., Nicco C., Chereau C., Goulvestre C., Alexandre J., Alves A., et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65 (2005) 948-956
2. Hileman E.O., Liu J., Albitar M., Keating M.J., and Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 53 (2004) 209-219
3. Cabello C.M., Bair III W.B., and Wondrak G.T. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 8 (2007) 1022-1037
4. Fruehauf J.P., and Meyskens Jr. F.L. Reactive oxygen species: a breath of life or death?. Clin Cancer Res 13 (2007) 789-794
5. Fruehauf J.P., and Trapp V. Reactive oxygen species: an Achilles' heel of melanoma?. Expert Rev Anticancer Ther 8 (2008) 1751-1757
6. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Update 8 (2005) 85-97
7. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 7 (2006) 407-421
8. Verrax J., Stockis J., Tison A., Taper H.S., and Calderon P.B. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol 72 (2006) 671-680
9. Loewe R., Valero T., Kremling S., Pratscher B., Kunstfeld R., Pehamberger H., et al. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res 66 (2006) 11888-11896
10. Wang C.C., Chiang Y.M., Sung S.C., Hsu Y.L., Chang J.K., and Kuo P.L. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett 259 (2008) 82-98
11. Cabello C.M., Bair III W.B., Lamore S.D., Bause A.S., Azimian S., and Wondrak G.T. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med 46 (2009) 220-231
12. Fry F.H., Holme A.L., Giles N.M., Giles G.I., Collins C., Holt K., et al. Multifunctional redox catalysts as selective enhancers of oxidative stress. Org Biomol Chem 3 (2005) 2579-2587
13. Magda D., and Miller R.A. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 16 (2006) 466-476
14. Wondrak G.T. NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med 43 (2007) 178-190
15. Berger T.G., Dieckmann D., Efferth T., Schultz E.S., Funk J.O., Baur A., et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 14 (2005) 1599-1603
16. Cen D., Brayton D., Shahandeh B., Meyskens Jr. F.L., and Farmer P.J. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 47 (2004) 6914-6920
17. Kirshner J.R., He S., Balasubramanyam V., Kepros J., Yang C.Y., Zhang M., et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7 (2008) 2319-2327
18. Tuma R.S. Reactive oxygen species may have antitumor activity in metastatic melanoma. J Natl Cancer Inst 100 (2008) 11-12
19. Brar S.S., Kennedy T.P., Sturrock A.B., Huecksteadt T.P., Quinn M.T., Whorton A.R., et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am J Physiol Cell Physiol 282 (2002) C1212-C1224
20. Wittgen H.G., and van Kempen L.C. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 17 (2007) 400-409
21. Fried L., and Arbiser J.L. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 21 (2008) 117-122
22. Criddle D.N., Gillies S., Baumgartner-Wilson H.K., Jaffar M., Chinje E.C., Passmore S., et al. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem 281 (2006) 40485-40492
23. Ernster L. DT-diaphorase. Methods Enzymol 10 (1967) 309-317
24. Wilson G.S. Determination of oxidation-reduction potentials. Methods Enzymol 54 (1978) 396-410
25. VanderJagt D.J., Garry P.J., and Hunt W.C. Ascorbate in plasma as measured by liquid chromatography and by dichlorophenolindophenol colorimetry. Clin Chem 32 (1986) 1004-1006
26. Yamashita T., and Butler W.L. Photoreduction and photophosphorylation with tris-washed chloroplasts. Plant Physiol 43 (1968) 1978-1986
27. Mayer D., Naumann R., Edler L., and Bannasch P. Investigation by amperometric methods of intracellular reduction of 2,6-dichlorophenolindophenol in normal and transformed hepatocytes in the presence of different inhibitors of cellular metabolism. Biochim Biophys Acta 1015 (1990) 258-263
28. Kumar S., and Acharya S.K. 2,6-Dichloro-phenol indophenol prevents switch-over of electrons between the cyanide-sensitive and -insensitive pathway of the mitochondrial electron transport chain in the presence of inhibitors. Anal Biochem 268 (1999) 89-93
29. Wolchok J.D., Williams L., Pinto J.T., Fleisher M., Krown S.E., Hwu W.J., et al. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 13 (2003) 189-196
30. Vad N.M., Yount G., Moore D., Weidanz J., and Moridani M.Y. Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J Pharm Sci 98 (2009) 1409-1425
31. MSDS: 2,6-Dichloroindophenol sodium salt (CAS#620-45-1). Sigma-Aldrich Version 1.5, 01/31/2006.
32. Wondrak G.T., Jacobson M.K., and Jacobson E.L. Antimelanoma activity of apoptogenic carbonyl scavengers. J Pharmacol Exp Ther 316 (2006) 805-814
33. Ross D., and Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382 (2004) 115-144
34. Baigi M.G., Brault L., Neguesque A., Beley M., Hilali R.E., Gauzere F., et al. Apoptosis/necrosis switch in two different cancer cell lines: influence of benzoquinone- and hydrogen peroxide-induced oxidative stress intensity, and glutathione. Toxicol In Vitro 22 (2008) 1547-1554
35. Fukuyo Y., Inoue M., Nakajima T., Higashikubo R., Horikoshi N.T., Hunt C., et al. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Cancer Res 68 (2008) 6324-6330
36. Noonan E., Giardina C., and Hightower L. Hsp70B' and Hsp72 form a complex in stressed human colon cells and each contributes to cytoprotection. Exp Cell Res 314 (2008) 2468-2476
37. Baron V., Adamson E.D., Calogero A., Ragona G., and Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 13 (2006) 115-124
38. Shen Y., Wang J., Yang T., Li Y., Jiang W., Guan Z., et al. Platinums sensitize human epithelial tumor cells to lymphotoxin alpha by inhibiting NFkappaB-dependent transcription. Cancer Biol Ther 7 (2008) 1407-1414
39. Sarkar D., Su Z.Z., Lebedeva I.V., Sauane M., Gopalkrishnan R.V., Valerie K., et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 99 (2002) 10054-10059
40. Scott D.W., and Loo G. Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 25 (2004) 2155-2164
41. Chow A.M., and Brown I.R. Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones 12 (2007) 237-244
42. Wondrak G.T., Jacobson M.K., and Jacobson E.L. An emerging molecular target in melanoma: cellular carbonyl stress and the inhibition of mitochondrial survival pathways by carbonyl scavenger agents. Curr Cancer Ther Rev 1 (2005) 271-276
43. Hocker T.L., Singh M.K., and Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128 (2008) 2575-2595
44. Han E.S., Muller F.L., Perez V., Qi W., Liang H., Xi L., et al. The in vivo gene expression signature of oxidative stress. Physiol Genomics (2008)
45. Paine-Murrieta G.D., Taylor C.W., Curtis R.A., Lopez M.H., Dorr R.T., Johnson C.S., et al. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 40 (1997) 209-214
46. Abdelmohsen K., Gerber P.A., von Montfort C., Sies H., and Klotz L.O. Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43: role of glutathione and tyrosine phosphatases. J Biol Chem 278 (2003) 38360-38367
47. Schmieder P.K., Tapper M.A., Kolanczyk R.C., Hammermeister D.E., Sheedy B.R., and Denny J.S. Discriminating redox cycling and arylation pathways of reactive chemical toxicity in trout hepatocytes. Toxicol Sci 72 (2003) 66-76
48. Lau S.S., Hill B.A., Highet R.J., and Monks T.J. Sequential oxidation and glutathione addition to 1,4-benzoquinone: correlation of toxicity with increased glutathione substitution. Mol Pharmacol 34 (1988) 829-836
49. Bratton S.B., Lau S.S., and Monks T.J. The putative benzene metabolite 2,3, 5-tris(glutathion-S-yl)hydroquinone depletes glutathione, stimulates sphingomyelin turnover, and induces apoptosis in HL-60 cells. Chem Res Toxicol 13 (2000) 550-556
50. Hadler H.I., Alt S.K., and Falcone A.B. Conjugation of 2,6-dichloroindophenol with mitochondrial thiol groups. J Biol Chem 241 (1966) 2886-2890
51. Dupuy C., Kaniewski J., Ohayon R., Deme D., Virion A., and Pommier J. Nonenzymatic NADPH-dependent reduction of 2,6-dichlorophenol-indophenol. Anal Biochem 191 (1990) 16-20
52. Sharp S.Y., Boxall K., Rowlands M., Prodromou C., Roe S.M., Maloney A., et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67 (2007) 2206-2216
53. Wilson M.W., Schelonka L.P., Siegel D., Meininger A., and Ross D. Immunohistochemical localization of NAD(P)H:quinone oxidoreductase in conjunctival melanomas and primary acquired melanosis. Curr Eye Res 22 (2001) 348-352
54. Danson S., Ward T.H., Butler J., and Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev 30 (2004) 437-449
55. Lewis A.M., Ough M., Hinkhouse M.M., Tsao M.S., Oberley L.W., and Cullen J.J. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 43 (2005) 215-224
56. Seng S., Avraham H.K., Birrane G., Jiang S., Li H., Katz G., et al. NRP/B mutations impair Nrf2-dependent NQO1 induction in human primary brain tumors. Oncogene 28 (2009) 378-389
57. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 59 (1999) 4095-4099
58. Bruge F., Virgili S., Cacciamani T., Principi F., Tiano L., and Littarru G.P. NAD(P)H:quinone oxidoreductase (NQO1) loss of function in Burkitt's lymphoma cell lines. Biofactors 32 (2008) 71-81
59. Fagerholm R., Hofstetter B., Tommiska J., Aaltonen K., Vrtel R., Syrjakoski K., et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40 (2008) 844-853
60. Nolan K.A., Timson D.J., Stratford I.J., and Bryce R.A. In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett 16 (2006) 6246-6254